A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

June 16, 2023

Frias et al. • 2023 • ENDO 2023

https://corcept.com/wp-content/uploads/2023/07/ECE2023-1.pdf

June 5, 2023

Simeoli et al. • 2023 • European Congress of Endocrinology

https://corcept.com/wp-content/uploads/2023/05/AACE2023-2.pdf

June 3, 2023

Donegan et al. • 2023 • AACE 2023

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing Syndrome

February 8, 2023

Moraitis et al • 2022 • ENDO 2022 Annual Meeting

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome

February 2, 2023

Moritis et al • 2022 • European Congress of Endocrinology